Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: Myriad is a healthcare company focused on molecular diagnostics and therapeutic product development. The company operates three segments: Research, Molecular Diagnostics, and Pharmaceutical Development. As of the filing date, the company is in the process of separating its research and pharmaceutical businesses into a new independent entity, Myriad Pharmaceuticals, Inc. (MPI), via a tax-free spin-off.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2009 | Nine Months Ended Mar 31, 2009 | Nine Months Ended Mar 31, 2008 |
|---|---|---|---|
| Total Revenue | $87,487 | $245,513 | $166,773 |
| Net Income (Loss) | $25,318 | $60,975 | $(17,696) |
| Operating Income (Loss) | $22,311 | $53,389 | $(28,133) |
| Diluted EPS | $0.25 | $0.62 | $(0.20) |
| Cash and Cash Equivalents | $200,685 | $200,685 | $142,392 |
| Total Marketable Securities | $334,157 | $334,157 | $182,322 |
| Net Cash from Operating Activities | N/A | $45,113 | $(8,104) |
Liquidity: Total cash, cash equivalents, and marketable investment securities increased to $534.8 million as of March 31, 2009, up from $420.1 million at June 30, 2008. The company reports no long-term debt.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 42% for the three months and 47% for the nine months ended March 31, 2009, compared to the prior year. This was driven primarily by a 47% (quarterly) and 52% (year-to-date) increase in molecular diagnostic revenue due to higher testing volumes.
- Profitability Turnaround: The company reported a net income of $25.3 million for the quarter and $61.0 million for the nine-month period, a significant improvement from net losses of $4.6 million and $17.7 million in the comparable 2008 periods.
- Expense Reductions: Research and development (R&D) expenses decreased 43% quarterly and 35% year-to-date. Key drivers included the discontinuance of an Alzheimer's disease drug candidate and a $9 million reduction in a sublicense fee accrual for Encore Pharmaceuticals.
- Investment Impairment: The company recorded a $2.0 million other-than-temporary impairment loss on marketable investment securities related to Lehman Brothers Holdings, Inc.
Guidance, Outlook, and Risks
Management Commentary: Management attributes revenue growth to successful marketing campaigns and wider acceptance of molecular diagnostic products. However, they note that economic turmoil, job losses, and reduced insurance coverage may dampen future revenue growth rates. The company expects R&D and SG&A expenses to fluctuate based on clinical trial progress and new product launches.
Corporate Restructuring: The company is proceeding with the spin-off of its research and pharmaceutical businesses into MPI. Approximately $185 million in cash and substantially all assets of these businesses will be contributed to MPI. The spin-off is subject to SEC approval of the Form 10 registration statement.
Risks and Contingencies:
- Clinical Trial Uncertainty: Future expenses and revenues for drug candidates (e.g., Azixa, MPC-4326) are highly uncertain due to the risks of clinical trial failure, regulatory delays, and enrollment challenges.
- Market Risk: The company holds significant marketable securities, including auction rate securities and bonds from financial institutions. While unrealized losses are currently deemed temporary, market volatility could impact liquidity and valuation.
- Spin-off Execution: The separation of businesses is subject to regulatory conditions and market factors; the Board retains the right to halt the distribution if deemed not in the best interest of shareholders.
Investor Verification Checklist
- Spin-off Status: Verify the effectiveness of the Form 10 registration statement for Myriad Pharmaceuticals, Inc. (MPI) and the timeline for the distribution of shares to stockholders.
- Investment Portfolio Quality: Review the composition of the $334 million marketable securities portfolio, specifically the status of auction rate securities and exposure to financial institutions, to assess potential future impairments.
- Clinical Trial Progress: Monitor updates on Phase 2 trials for Azixa and Phase 1 trials for MPC-3100, MPC-2130, and MPC-9055, as these drive future R&D costs and potential revenue.
- Revenue Sustainability: Assess whether the 47-52% revenue growth in molecular diagnostics can be sustained given the cited economic headwinds and potential saturation in the Ob/Gyn market.
- Bad Debt Exposure: Note the increase in bad debt expense ($1.4 million quarterly increase) and the allowance for doubtful accounts ($4.6 million) relative to the growth in trade receivables.